

# Taking Immunotherapy Seriously: New Targets and Combinations



CANCER  
**PROGRESS**  
*by Defined Health*

March 4 – 5, 2014  
Conrad New York

# Taking Immunotherapy Seriously: *New Targets and Combinations*

## **Moderator:**

- Axel Hoos, MD, PhD, Vice President, Oncology R&D, GlaxoSmithKline; Co-Director, Cancer Immunotherapy Consortium (CIC)

## **Panelists:**

- Jeff Bockman, PhD, VP, Defined Health
- Ira Mellman, PhD, VP, Research Oncology, Genentech
- Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen
- Michel Sadelain, MD, PhD, Director, Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center
- Lauren V. Wood, MD, Senior Clinical Investigator, Vaccine Branch, National Cancer Institute



**CANCER**  
**PROGRESS**  
*by Defined Health*


## Topics:

- Antigen Discovery
- Immune Biomarkers
- Combination Therapy
- Collaboration





**CANCER**  
**PROGRESS**  
*by Defined Health*

# Cancer Immunotherapy Space



# The Cancer Immunity Cycle





Adapted from: *J Clin Invest.* 2010; 120(1):76-80

# Taking Cancer Immunotherapy Seriously

- *Enhancing basic cancer biology research to undergird clinical translation and development of cancer immunotherapy.* We need to have consistent pre-clinical models that will help us:
  - Maximize therapeutic potency
  - Identify off treatment toxicity
  - Identify biomarkers of response

**Critical issue because as potency of cancer immunotherapy is likely to correlate with toxicity.**



**CANCER**  
**PROGRESS**  
*by Defined Health*

**March 4 – 5, 2014**  
**Conrad New York**

# Taking Cancer Immunotherapy Seriously

➤ *Cellular therapies are here to stay:*

ATL ---> CAR ---> TCR ---> NK Cells ---> Dendritic Cell Vaccines

➤ *Ultimate in “personalized therapy” -----> ultimate biologic variability*

➤ **Challenges in characterization of product potency and consistency.**

➤ **Are there universal process that can be employed that will take anybody’s cells to a better level functionally?**

➤ **Manufacturing science: biologic and physical chemistry to bring the cost price of immunotherapy down.**

➤ **Early optimization of platform approach- may require regulatory flexibility.**

**CANCER**  
**PROGRESS**  
*by Defined Health*

March 4 – 5, 2014  
Conrad New York